Eli Lilly's (LLY +0.2%) dulaglutide treatment for type 2 diabetes performs well in three Phase...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly's (LLY +0.2%) dulaglutide treatment for type 2 diabetes performs well in three Phase III studies, meeting the primary endpoints as measured by lower levels of hemoglobin A1c, which helps indicate blood sugar control. The most frequently reported side-effects were gastrointestinal-related. Other studies of dulaglutide are taking place, with two due to conclude in the next few months. (PR)